EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.
You may also be interested in...
EU Proposals On R&D Funding Transparency Could Increase Pressure On Companies Negotiating Drug Prices
The draft Directive that was published last month with a draft Regulation for reforming the EU’s medicines legislation includes proposals for companies to publicly declare financial support received from a public authority or publicly funded body for R&D activities.
EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’
Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.
EU Data Protection Reductions Would ‘Irretrievably Sabotage’ Pharma Industry
With the proposals for an overhaul of the EU pharmaceutical legislation tentatively scheduled for publication on 29 March, the European industry federation EFPIA claims that the plans as currently drafted will drive investment away and damage the industry’s ability to compete at global scale. But the European Commission insists the revision will boost industry's global competitiveness and innovative power.